In vivo morphologic changes in the rat osteoclast induced by gallium nitrate: The result of toxicity or other effects?

Mineral and Electrolyte Metabolism

Volumn 25, Issue 3, 1999, Pages 127-134

  Gruber, Helen E ^a   Norton, H James ^a   Singer, Frederick R ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Bone; Cell pathology; Gallium nitrate; Histomorphometry; Osteoclast; Resorption; Ultrastructure

Indexed keywords

ANTINEOPLASTIC AGENT; GALLIUM NITRATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; HYPERCALCEMIA; MALE; NONHUMAN; OSTEOCLAST; PAGET BONE DISEASE; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; GALLIUM; MALE; OSTEOCLASTS; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS;

ANIMALIA;

EID: 0032802222     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057436     Document Type: Article

References (42)

1. Warrell RPJ, Bochman RS, Coonley CJ, Isacs M, Staszewski H: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984;73:1487-1490.
2. Warrell RPJ, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia. Ann Intern Med 1988;108:669-674.
3. Matkovic V, Apseloff G, Jelic T, Whitacre C, Gerber N: Long-term effects of gallium nitrate in patients with Paget's disease of bone. J Bone Miner Res 1991;6(suppl 1):295.
4. Bockman RW, Wilhelm F, Siris E, et al: A multicenter, prospective trial of gallium nitrate in patients with advanced Paget's disease of bone. J Clin Endocrinol Metab 1995;80:595-602.
5. Heró H, Okabe T: Gallium alloys as dental restorative materials: A research review. Cells Mater 1994;4:409-418.
6. Wakley GK, Garand J, Brown D, Szukalski BW, Bell NH, Turner RT: Effects of gallium on bone in the rat. J Bone Miner Res 1992;7:11-19.
7. Blair HC, Teitelbaum SL, Tan H, Schlesinger PH: Reversible inhibition of osteoclastic activity by bone-bound gallium. III. J Cell Biochem 1992;48:401-410.
8. Cournot-Witmer G, Bourdeau A, Liebeherr M, et al: Bone remodelling in gallium nitrate-treated rats. Calcif Tissue Int 1987;40:270-275.
9. Donnelly R, Bockman R, DiCarlo E, Betts F, Boskey A: The effect of gallium nitrate on healing of vitamin D-and phosphate-deficient rickets in the immature rat. Calcif Tissue Int 1993; 53:400-410.
10. Donnelly R, Bockman RS, Doty SB, Boskey AL: Bone particles from gallium-treated rats are reistant to resorption in vivo. Bone Miner 1991; 12:167-179.
11. Guidon PTJ, Salvatori R, Bockman RS: Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels. J Bone Miner Res 1993;8:103-112.
12. Lakatos P, Mong S, Stern PH: Gallium nitrate inhibits bone resorption and collagen synthesis in neonatal mouse calvariae. J Bone Miner Res 1991;6:1121-1126.
13. Merryman JI, Capen CC, Rosol TJ: Effects of gallium nitrate in nude mice bearing a canine adenocarcinoma (CAC-8) model of humoral hypercalcemia of malignancy. J Bone Miner Res 1994;9:725-732.
14. Aoki Y, Lipsky MM, Fowler BA: Alteration in protein synthesis in primary cultures of rat kidney proximal tubule epithelial cells by exposure to gallium, indium, and arsenite. Toxicol Appl Pharmacol 1990;106:462-468.
15. Berggren MM, Burns LA, Abraham RT, Powis G: Inhibition of protein tyrosine phosphatase by the antitumor agent gallium. Cancer Res 1993;53:1862-1866.
16. Boskey AL, Ziehzheck P, Guidon P, Doty SB: Gallium nitrate inhibits alkaline phosphatase activity in a differentiating mesenchymal cell culture. Bone Miner 1993;20:179-192.
17. Roodman GD: Advances in bone biology: The osteoclast. Endocr Rev 1996;17:308-332.
18. Väänänen HK, Horton M: The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995;108:2729-2732.
19. Teti A, Marchisio PC, Zallone AZ: Clear zone in osteoclast function: Role of podosomes in regulation of bone-resorbing activity. Am J Physiol 1991;261:C1-C7.
20. Gruber HE, Marshall GJ, Nolasco LM, Kirchen ME, Rimoin DL: Alkaline and acid phosphatase demonstration in human bone and cartilage: Effects of fixation intervals and methacrylate embedments. Stain Technol 1988; 63:299-306.
21. Thompson ER, Baylink DJ, Wergedal JE: Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 1975;97:283-289.
22. Liu C, Rader JI, Gruber HE, Baylink DJ: Acute reduction in osteoclast number during bone repletion. Metab Bone Dis Rel Res 1982;4:201-209.
23. Liu C, Evacki M, Howard GA: In vivo calvarial bone cell responses to dietary perturbations and the implications for mineral homeostasis. Proc Soc Exp Biol Med 1989;190:385-392.
24. Owen M: Cellular dynamics of bone; in The Biochemistry and Physiology of Bone. New York, Academic Press, 1971, vol 3, pp 271-298.
25. Parfitt AM: The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: Bone turnover and plasma calcium regulation. Metabolism 1976;25:909-955.
26. McGuire JL, Marks SCJ: The effects of parathyroid hormone on bone cell structure and function. Clin Orthop Rel Res 1974;100:392-405.
27. Miller SC, Jee WSS, Kimmel DB, Woodbury L: Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calcif Tissue Res. 1977;22: 243-252.
28. Miller SC, Jee WSS: Ethane-1-hydroxy-1,1-diphosphonate (EHDP) effects of growth and modeling of the rat tibia. Calcif Tissue Res 1975; 18:215-231.
29. Gruber HE, Ivey JL, Thompson ER, Chesnut CHI, Baylink DJ: Osteoblast and osteoclast cell number and cell activity in postmenopausal osteoporosis. Miner Electrolyte Metab 1986;12: 246-254.
30. Qui MC, Matthews C, Parfitt AM: Osteoclastic resorption of osteoid in secondary hyperparathyroidism: in Clinical Disorders of Bone and Mineral Metabolism. Amsterdam. Excerpta Medica, 1983, pp 209-212.
31. Evans RA, Howlett CR, Dunstan CR, Hills E: The effect of long-term low-dose diphosphonate treatment on rat bone. Clin Orthop Rel Res 1982;165:290-299.
32. Hall TJ, Chambers TJ: Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner 1990;8:211-216.
33. Mills BG, Masuoka LS, Graham CCJ, Singer FR, Waxman AD: Gallium-67 citrate localization in osteoclast nuclei of Paget's disease of bone. J Nucl Med 1988;29:1083-1087.
34. Mills BG, Haroutinian A, Holst P, Bordier PJ, Tun-Chot S: Ultrastructural and cellular changes at the costochondral junction following in vivo treatment with calcitonin or calcium chloride in the rabbit; in Endocrinology 1971. Proc Third Int Symp. London, Heinemann Medical, 1972, pp 79-88.
35. Plasmans CMT, Jap PHK, Kuijpers W, Sloof TJHH: Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int 1980;32:247-256.
36. Miller SC, Jee WSS: The effect of dichloromethylene diphosphonate. a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Res 1979;193:439-462.
37. Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
38. Weisbrode SW, Capen CC: Ultrastructural evaluation of the effects of calcitonin on bone in hypoparathyroidectomized rats administered vitamin D. Am J Pathol 1974;77:455-464.
39. Lucht U: Effects of calcitonin on osteoclasts in vivo. Z Zellforsch 1973;145:75-87.
40. Kallio DM, Garant PR, Minkin C: Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Res 1972;39:205-216.
41. Accardo G, Aleotti A, Ricci D, Pazzi A: Support for the clinical use of calcitonin: Electron microscope study of the functional state of bone cells of rats after chronic treatment with calcitonin. Curr Ther Res 1982;31:422-433.
42. Minkin C: Inhibition of parathyroid hormone stimulated bone resorption in vitro by the antibiotic mithramycin. Calcif Tissue Res 1973;13: 249-257.